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Rhinovirus (RV) accounts for 75 to 80% of virus-induced exacerba- relevant RV infections associated with asthma exacerbations that
tions of asthma among children and young adults. A wide diversity of
RV genotypes cause recurrent infections that lead to attacks of wheez-
ing that begin in infancy. After 3 years of age, it is now clear that atopy
and allergic airway inﬂammation are major risk factors for attacks of
asthma provoked by RV (Heymann et al., 2004; Soto-Quiros et al.,
2012). Together with efforts to understanding mechanisms underlying
the role of RV in causing asthma exacerbations, current research has
been focused on determining whether there are strains of RV that are
more likely to induce an attack of asthma to guide the development of
new treatments, including vaccines.
A signiﬁcant challenge for developing vaccines against RV is that
well over 150 strains of RV have been identiﬁed. These strains belong
to three genetically related groups; RV-A, B, and C. Recent investigations
indicate that some strains may be more likely to provoke an asthma at-
tack and may represent targets for an effective vaccine. In population-
based studies of children and adults experiencing an attack of asthma,
group A and C strains have been detectedmore frequently. Recent stud-
ies from Australia and Costa Rica indicate that the group C strains may
trigger exacerbations more often than group A strains (Soto-Quiros
et al., 2012; Bizzintino et al., 2011); however, studies from the United
States indicate that the group A viruses play an equally important role
(Khetsuriani et al., 2008; Kennedy et al., 2014).
Deciphering the pathogenic role of each RV strain in provoking asth-
ma symptoms has also been challenging. PCR tests for RV are frequently
positive in longitudinal studies designed to determine the rate of infec-
tions (e.g., approximately 0.4 to 0.6 infections/month in children)
(Winther et al., 2006). However, many of these positive tests either rep-
resent sub-clinical infections, or identify recent, but not acute infections.
Unfortunately, cultures underestimate the prevalence of RV infections,
because the group C strains cannot be detected using currently available
culture systems. For these reasons, the research paper in this issue of
EBioMedicine by Niespodziana and colleagues addresses a very impor-
tant problem (Niespodziana et al., 2015–in press). Their paper describes
themeasurement RV group and strain speciﬁc antibody responses to re-
combinant RV related proteins and fragments. The results indicate that
IgG1 isotype antibody responses speciﬁc for the N-terminal fragments
of the VP1 coat protein may serve as serologic markers for clinicallyDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.11.012.
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2015–in press).
More speciﬁcally, the paper by Niespodziana et al. describes the
production of recombinant RV coat proteins (VP1–4), together with
nonstructural replication proteins, and the major epitope containing
N-terminal fragments of VP1 proteins derived from4RV strains (includ-
ing two strains of group A RV's, and one strain each from the group B
and group C RV's) (Niespodziana et al., 2015–in press). This is a signiﬁ-
cant achievement which allowed the investigators to evaluate antibody
isotype responses to these recombinant reagents by ELISA. The assess-
ments were done using sera obtained prior to and following the inocu-
lation of subjects with RV-16, a group A strain. The subjects included
those with mild asthma, moderate asthma, and healthy, non-atopic
controls. The results revealed that the experimental infection with
RV-16 induced a strain speciﬁc boost of antibody production by day
42 (6 weeks post-inoculation), predominantly against the N-terminal
epitope on VP1. This response was stronger among the subjects with
moderate asthma and correlated with the severity of upper and lower
respiratory tract symptoms (Niespodziana et al., 2015–in press).
To learnwhethermeasurements of IgG1 to theN-terminal portion of
VP1 coat proteins might be useful as serologic tests for the most com-
mon, clinically relevant strains of RV, the authors note that further
work is needed. For example, comparative sequence modeling predicts
that all RV-C VP1 proteins are shorter by 21 residues compared to VP1
proteins from RV-A strains (Basta et al., 2014). Additionally, IgG1 anti-
body titers to RV-C VP1 proteins recently were shown to be reduced
compared to titers directed against RV-A and B strains in plasma sam-
ples from children presenting to the ER with asthma exacerbations
(Iwasaki et al., 2014). Of course, the timing of sample collection may
be critical for evaluating these responses. Unfortunately, a group C strain
of RV is not yet available for experimental challenge, but the authors
point out that it will be important to obtain more data regarding the
immunogenicity of RV-C VP1 proteins, especially the N-terminal frag-
ments, to gain more information relevant to vaccine development.
Also interesting is that IgG1 antibody to the N-terminal VP1 fragments
from RV groups A, B, and C was detectable before virus inoculation,
followed by a signiﬁcant group A strain speciﬁc boost by day 42 after
inoculation. Not known is how long these IgG1 titers would remain
elevated post-infectionwhich could confound efforts to identify a strain
linked to a subsequent RV-induced asthma attack, especially among
children who get RV infections more frequently.ense (http://creativecommons.org/licenses/by/4.0/).
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may be further complicated by other picornavirus strains that can cause
asthma attacks, including enterovirus-68 which recently caused hospital
admissions and ER visits for asthma in the U.S. this fall. Thus, other treat-
ment strategies remain under investigation and include the development
of innate anti-viral therapies (e.g., administering type I or type III inter-
ferons); however, costs, side effects, and how these drugs should be ad-
ministered (seasonally, or at the time of an acute infection) will need to
be considered. Alternatively, treatments to reduce allergic inﬂammation
in the airwaymay also help to counter the asthmatic effects of RV. In sup-
port of this approach, the administration of omalizumab (anti-IgE anti-
body) to inner-city children with asthma in the US virtually illuminated
the seasonal increases in asthma exacerbations in the spring and fall
(Busse et al., 2011). This treatment effect included a subset of children
who tested positive for RV. As these treatment strategies are compared
and evaluated, the research results described byNiespodziana et al. clear-
ly represent a step in the right direction to help us develop newmethods
to minimize the adverse effects of RV infections in the asthmatic
population.
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